Substances · Cathinone derivatives
2-CMC
- Preferred name
- 2-CMC
- IUPAC name
- 1-(2-chlorophenyl)-2-(methylamino)propan-1-one
- Parent CAS number (reference)
- 1246911-70-5
- Molecular formula
- C10H12ClNO
- Molecular weight
- 197.66 g/mol
- InChIKey
- UHVGPEBZWPKWNT-UHFFFAOYSA-N
- PubChem
- CID 112693018
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
2-Chloromethcathinone 2CMC 2 CMC 2-Chloro-N-methylcathinone
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
2-CMC (2-Chloromethcathinone)
Receptor Telemetry & Mechanism of Action
Steric hindrance from the ortho-chlorine atom dramatically alters transporter recognition compared to 3-CMC and 4-CMC. In rat brain synaptosomes (Walther et al., 2018), 2-CMC acts as a selective norepinephrine and dopamine releasing agent (NET EC50 = 93 ± 6 nM; DAT EC50 = 179 ± 22 nM) with nearly 20-fold weaker serotonin release than 4-CMC (SERT EC50 = 2,815 ± 620 nM; SERT/DAT ratio ~15.7). Consequently, 2-CMC produces catecholaminergic stimulation devoid of a heavy serotonergic 'roll'.
Biotransformation & Active Metabolites
2-Chlorocathinone (ortho-chlorocathinone) and dihydro-2-CMC are expected analytical metabolites based on methcathinone pathways; reference-standard suppliers note that specific human metabolic and toxicological studies have not yet been published.
Temporal Pharmacokinetics
Mild, clear-headed, functional psychostimulant profile predicted from its NDRA pharmacology—offering wakefulness, conversational alertness, and modest dopaminergic mood lift without serotonergic haziness.
- Onset 20–45 minutes oral (tentative class estimate; 5–15 minutes mucosal)
- Peak Window 45–90 minutes
- Total Window 2.5–4.5 hours oral (tentative class estimate; 1.5–2.5 hours mucosal)
- Residual / Half-Life 2–6 hours of residual adrenergic wakefulness; human elimination half-life and clinical toxicokinetics are unverified.
No independent human quantitative brackets trials or TripSit/PsychonautWiki tables exist for 2-CMC. Because 2-CMC is ~6.9-fold weaker at DAT than 3-CMC and largely inactive at SERT, users expecting a 4-MMC/4-CMC empathogenic surge face a major trap: escalating past ~150–180 mg cannot unlock serotonergic mood elevation because NET potency (EC50 = 93 nM) outpaces DAT (179 nM), driving disproportionate tachycardia, hypertension, and peripheral vasoconstriction instead.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
25–40 mg (tentative SAR estimate)
Subtle mental clearing, reduced drowsiness, and slight increase in task attentiveness.
Minimal somatic sensation; faint uptick in resting pulse.
40–75 mg (tentative SAR estimate)
Crisp wakefulness, calm focus, light sociability, and mild mood elevation without perceptual distortion.
Mild appetite suppression, dry mouth, and gentle adrenergic energy.
75–130 mg (tentative SAR estimate)
Clear dopaminergic motivation, talkativeness, enhanced alertness, and social confidence with minimal empathogenic softness.
Noticeable heart-rate and blood-pressure elevation, sweating, mild jaw tension, and cool fingertips.
130–180 mg (tentative SAR estimate)
Restless, jittery stimulation, racing thoughts, hyper-vigilance, and rising adrenergic tension.
Pronounced tachycardia (NET-driven), vasoconstriction, bruxism, tremor, and post-peak insomnia.
180–250+ mg (tentative SAR estimate)
Acute anxiety, panic, irritability, working-memory disruption, and potential paranoid overstimulation.
Severe hypertension, chest tightness, palpitations, peripheral vasospasm, hyperthermia, and seizure risk.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Potent norepinephrine and dopamine release (NET EC50 = 93 nM) under MAO inhibition triggers life-threatening hypertensive crisis, cerebral hemorrhage, and hyperthermia.
Synergistic noradrenergic vasoconstriction and cardiac workload risk acute arrhythmias, vasospasm, and myocardial ischemia.
Lowers seizure threshold while compounding noradrenergic hypertension and convulsion risk.
Elevated Hazard — Avoid
Adds heavy noradrenergic cardiovascular and thermoregulatory strain onto serotonergic entactogens.
Masks subjective sedation, leading to excessive depressant intake and cardiovascular/dehydration strain.
Caution / Receptor Attenuation
Amplifies 2-CMC's prominent NET-mediated heart-rate elevation, jitteriness, and peripheral coldness.
SNRIs can additively increase noradrenergic blood-pressure and heart-rate elevation.
Structural Isomer & Sibling Comparison
Within the CMC triad, 2-CMC is by far the least potent and most catecholamine-selective isomer: it is ~6.9-fold less potent at DAT than 3-CMC (179 nM vs. 26 nM) and ~19.5-fold weaker at SERT than 4-CMC (2,815 nM vs. 144 nM). Pharmacologically, 2-CMC parallels ortho-methylated 2-MMC—acting as a clearer, non-empathogenic stimulant, though ~2.2-fold less potent at DAT than 2-MMC (81 nM).
Physicochemical Stability & Storage
Form: White to off-white crystalline solid or clear crystal shards as the monohydrochloride salt (recrystallized HCl mp 172–174 °C; lit. 159–161 °C). · Soluble in PBS (pH 7.2, ~5 mg/mL), ethanol (~5 mg/mL), DMF (~5 mg/mL), and DMSO (~10 mg/mL).
Subject to beta-keto reduction and instability in biological/aqueous media; store sealed, dry, and protected from light at cool temperatures.
Cross-Tolerance & Dependence Profile
Expected cross-tolerance with all dopaminergic/noradrenergic stimulants (2-MMC, 3-CMC, amphetamine), halving in ~3–7 days and returning to baseline in 1–2 weeks. Psychological repeated exposure cravings occur if chased for mood elevation, while long-term human toxicity remains unstudied.
Chemical Architecture & Structural Profile
2-CMC (1-(2-chlorophenyl)-2-(methylamino)propan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C10H12ClNO and a molar mass of 197.66 g/mol. The parent molecule is indexed under CAS registry number 1246911-70-5 and in the NCBI PubChem database as CID 112693018 (Standard InChIKey: UHVGPEBZWPKWNT-UHFFFAOYSA-N). This molecule shares its empirical formula (C10H12ClNO) with positional or structural isomers; unambiguous analytical identification requires matching the full IUPAC structure, CAS number (1246911-70-5), and spectroscopic profile.
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), 2-CMC is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- EUDA / National Chemical & Controlled Substance Registry (IE) — National Regulatory Authority (IE) (2026-11-12)